This Article Full Text Full Text (PDF) All Versions of this Article: 36/3/619    most recent 01.STR.0000155686.73908.3ev1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pantoni, L. Articles by Inzitari, D. Search for Related Content PubMed PubMed Citation Articles by Pantoni, L. Articles by Inzitari, D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Related Collections Other Treatment Behavioral Changes and Stroke

(Stroke. 2005;36:619.)
© 2005 American Heart Association, Inc.

Original Contributions

Efficacy and Safety of Nimodipine in Subcortical Vascular Dementia

A Randomized Placebo-Controlled Trial

Leonardo Pantoni, MD, PhD; Teodoro del Ser, MD; Andrea G. Soglian, MD; Silvia Amigoni, BSC, PhD; Giovanni Spadari, BSC; Daniela Binelli, BSC Domenico Inzitari, MD

From the Department of Neurological and Psychiatric Sciences (L.P., D.I.), University of Florence, Florence, Italy; Section of Neurology (T.D.S.), Hospital Severo Ochoa. Leganès, Madrid, Spain; Bayer SpA (A.G.S., G.S.), Medical Department, Milan, Italy; and Opis Data Srl (S.A., D.B.), Desio, Milan, Italy.

Correspondence to Dr Leonardo Pantoni, Department of Neurological and Psychiatric Sciences, University of Florence, Viale Morgagni 35, 50134 Florence, Italy. E-mail pantoni{at}neuro.unifi.it

Background and Purpose— Evidence of drug efficacy in vascular dementia (VaD) is scanty. Therapeutic trials should address VaD subtypes. We studied the efficacy and safety of the calcium antagonist nimodipine in subcortical VaD.

Methods— 242 patients defined as affected by subcortical VaD based on clinical (ICD-10) and computed tomography criteria were randomized to oral nimodipine 90 mg/d or placebo.

Results— 230 patients (121 nimodipine, mean age 75.2±6.1; 109 placebo, 75.4±6.0) were valid for the intention-to-treat analysis. At 52 weeks, the Sandoz Clinical Assessment Geriatric scale 5-point variation (primary outcome measure) did not differ significantly between the 2 groups. However, patients on nimodipine performed better than placebo patients in lexical production (P<0.01) and less frequently showed deterioration (3 or more point-drop versus baseline) on a Mini-Mental State Examination (28.1% versus 50.5%; ² P<0.01) and Global Deterioration Scale (P<0.05). Dropouts and adverse events were all significantly more common among placebo than nimodipine patients, particularly cardiovascular (30 versus 13; RR, 2.26; 95% CI, 1.11 to 4.60) and cerebrovascular events (28 versus 10; RR, 2.48; 95% CI, 1.23 to 4.98), and behavioral disturbances requiring intervention (22 versus 5; RR, 3.88; 95% CI, 1.49 to 10.12). A worst-rank analysis, performed to correct for the effect of the high dropout rate in the placebo group, showed additional significant differences in favor of nimodipine in Set Test and MMSE total scores.

Conclusions— Nimodipine may be of some benefit in subcortical VaD. Confirming previous results, the safety analysis of this study shows that in this high-risk population, nimodipine might protect against cardiovascular comorbidities.

Key Words: cognition • dementia • dementia, vascular • nimodipine

This article has been cited by other articles:

				S. Saddichha and V. Pandey Alzheimer's and Non-Alzheimer's Dementia: A Critical Review of Pharmacological and Nonpharmacological Strategies American Journal of Alzheimer's Disease and Other Dementias, May 1, 2008; 23(2): 150 - 161. [Abstract] [PDF]

				J. V. Bowler Modern concept of vascular cognitive impairment Br. Med. Bull., September 1, 2007; 83(1): 291 - 305. [Abstract] [Full Text] [PDF]

				H. Chui and I. Skoog Advances in Vascular Cognitive Impairment 2005 Stroke, February 1, 2006; 37(2): 323 - 325. [Full Text] [PDF]